IBI363
CIBI363C301
Phase 3 small_molecule active
Quick answer
IBI363 for iO Resistant sqNSCLC is a Phase 3 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- iO Resistant sqNSCLC
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active